New Breast Cancer Drug Tykerb From Glaxo May Be Within Months In EU

Armen Hareyan's picture
Advertisement

Glaxo is set to file for EU approval of it's new breast cancer drug Tykerb, reports The Observer.

While the source is not named in the report, it says that unlike Swiss made Herceptin - which is administered intravenously -

Advertisement